The selective BRAF inhibitor (BRAFi) vemurafenib is highly effective in treating metastatic melanomas and has been approved as a first-line therapeutic for metastatic melanoma cases that harbor V600 mutations in BRAF[2]. This evidence concerns the gene BRAF and metastatic melanoma.